Inspire Medical Systems Inc

Inspire Medical Systems Inc(INSP)股票分析

$71.110

-1.515 (-2.13%)收盤時

Loading chart…
最高
72.750
開盤
72.250
成交量加權均價
70.77
成交量
592.14K
市值
4.02B
最低
68.439
成交金額
41.90M
企業價值/稅息折舊攤銷前利潤(TTM)
134.37

Inspire Medical Systems, Inc. is a medical technology company. The Company focuses on the development and commercialization of advanced, minimally invasive solutions for patients with obstructive sleep apnea (OSA). Its proprietary Inspire therapy is neurostimulation technology that provides safe and effective treatment for moderate to severe obstructive sleep apnea. The Company's closed-loop solution continuously monitors a patient’s breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway. The Company sells its Inspire system to hospitals and ambulatory surgery centers (ASCs) in the United States (U.S.) and in select countries in Europe and Japan through a direct sales organization and sells its Inspire system in Singapore and Hong Kong through distributors. Its direct sales force engages in sales efforts and promotional activities focused on ear, nose and throat (ENT) physicians and sleep centers.

AI 分析 of Inspire Medical Systems Inc (INSP)

買進

Inspire Medical Systems Inc (INSP) is a good buy right now due to its current price of $71.11, which is below several analyst price targets indicating potential upside. Notably, Freedom Broker's target of $97 suggests a 36.4% upside from the current price. Additionally, the company reported a gross margin of 86.47% for Q1 2026, indicating strong profitability. However, the forward P/E ratio of 59.17 suggests that the stock may be overvalued if growth does not materialize as expected, representing a key risk.

分析師評級(5)

上檔空間 +104.35%
買進
3 買進
2 持有
0 賣出
目前: 71.11
最低
91.00
平均
145.31
最高
180.00

RBC Capital

2026-10-01

目標價

$75

Sector Perform

Freedom Broker

2026-09-21

目標價

$97

買進

Stifel

2026-09-11

目標價

$80

買進

Mizuho

2026-08-04

目標價

$65

優於大盤

JPMorgan

2026-08-04

目標價

$60

中性

估值指標

Inspire Medical Systems Inc(INSP)目前預期本益比為 59.17,5 年平均預期本益比為 48.04。

預期本益比

合理
5 年均值 P/E
48.04
目前P/E
59.17
高估
298.22
低估
-202.13

預期 EV/EBITDA

合理
5 年均值 EV/EBITDA
5.20
目前EV/EBITDA
134.37
高估
174.51
低估
-164.11

預期股價營收比

低估
5 年均值 P/S
8.23
目前P/S
2.37
高估
13.72
低估
2.74

Alphio AI 對 INSP 的價格情境

情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

樂

樂觀

樂觀 · 25%INSP

$195.33

情境價格

基

基準

基準 · 50%INSP

$174.83

情境價格

悲

悲觀

悲觀 · 25%INSP

$166.61

情境價格

持有 INSP 的大戶

B

Braidwell LP

+ 持有INSP

+24.47%

3個月報酬率

S

Soleus Capital Management, L.P.

+ 持有INSP

-6.31%

3個月報酬率

D

Deerfield Management Company, L.P.

+ 持有INSP

-6.60%

3個月報酬率

A

ADAR1 Capital Management, LLC

+ 持有INSP

-12.59%

3個月報酬率

INSP 常見問題 —— 由 Alphio AI 解答

Inspire Medical Systems, Inc. is a medical technology company. The Company focuses on the development and commercialization of advanced, minimally invasive solutions for patients with obstructive sleep apnea (OSA). Its proprietary Inspire therapy is neurostimulation technology that provides safe and effective treatment for moderate to severe obstructive sleep apnea. The Company's closed-loop solution continuously monitors a patient’s breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway. The Company sells its Inspire system to hospitals and ambulatory surgery centers (ASCs) in the United States (U.S.) and in select countries in Europe and Japan through a direct sales organization and sells its Inspire system in Singapore and Hong Kong through distributors. Its direct sales force engages in sales efforts and promotional activities focused on ear, nose and throat (ENT) physicians and sleep centers. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Inspire Medical Systems Inc (INSP) is a good buy right now due to its current price of $71.11, which is below several analyst price targets indicating potential upside. Notably, Freedom Broker's target of $97 suggests a 36.4% upside from the current price. Additionally, the company reported a gross margin of 86.47% for Q1 2026, indicating strong profitability. However, the forward P/E ratio of 59.17 suggests that the stock may be overvalued if growth does not materialize as expected, representing a key risk.

5 analysts cover INSP: 3 rate it Buy, 2 Hold and 0 Sell. The average price target is 145.31.

暫無貼文

註冊或登入後參與討論

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

開始交易